122 related articles for article (PubMed ID: 28239880)
21. Determinants of hepatocellular carcinoma in cirrhotic patients treated with nucleos(t)ide analogues for chronic hepatitis B.
Hsu YC; Wu CY; Lane HY; Chang CY; Tai CM; Tseng CH; Lo GH; Perng DS; Lin JT; Mo LR
J Antimicrob Chemother; 2014 Jul; 69(7):1920-7. PubMed ID: 24576950
[TBL] [Abstract][Full Text] [Related]
22. Incidence of hepatocellular carcinoma in chronic hepatitis B patients receiving nucleos(t)ide therapy: a systematic review.
Papatheodoridis GV; Lampertico P; Manolakopoulos S; Lok A
J Hepatol; 2010 Aug; 53(2):348-56. PubMed ID: 20483498
[TBL] [Abstract][Full Text] [Related]
23. Long-term outcomes of hepatitis B virus-related cirrhosis treated with nucleos(t)ide analogs.
Tsai MC; Chen CH; Hu TH; Lu SN; Lee CM; Wang JH; Hung CH
J Formos Med Assoc; 2017 Jul; 116(7):512-521. PubMed ID: 27720344
[TBL] [Abstract][Full Text] [Related]
24. Prognosis of hepatitis B-related liver cirrhosis in the era of oral nucleos(t)ide analog antiviral agents.
Kim CH; Um SH; Seo YS; Jung JY; Kim JD; Yim HJ; Keum B; Kim YS; Jeen YT; Lee HS; Chun HJ; Kim CD; Ryu HS
J Gastroenterol Hepatol; 2012 Oct; 27(10):1589-95. PubMed ID: 22554121
[TBL] [Abstract][Full Text] [Related]
25. A scoring model predicts hepatitis B e antigen seroconversion in chronic hepatitis B patients treated with nucleos(t)ide analogs: real-world clinical practice.
Geng M; Li Y; Gao F; Sun L; Yang X; Wang R; Chen J; Zhang Q; Wan G; Wang X
Int J Infect Dis; 2017 Sep; 62():18-25. PubMed ID: 28669850
[TBL] [Abstract][Full Text] [Related]
26. Effect of Nucleos(t)ide Analogue Therapy on Risk of Intrahepatic Cholangiocarcinoma in Patients With Chronic Hepatitis B.
Lee TY; Hsu YC; Yu SH; Lin JT; Wu MS; Wu CY
Clin Gastroenterol Hepatol; 2018 Jun; 16(6):947-954.e4. PubMed ID: 28951229
[TBL] [Abstract][Full Text] [Related]
27. Association of nucleos(t)ide analogue therapy with reduced risk of hepatocellular carcinoma in patients with chronic hepatitis B: a nationwide cohort study.
Wu CY; Lin JT; Ho HJ; Su CW; Lee TY; Wang SY; Wu C; Wu JC
Gastroenterology; 2014 Jul; 147(1):143-151.e5. PubMed ID: 24704525
[TBL] [Abstract][Full Text] [Related]
28. Prevalence and risk factors for viral blipping in chronic hepatitis B patients treated with nucleos (t) ide analogues.
Brahmania M; Brouwer WP; Hansen T; Mazzulli T; Feld J; Wong D; Kowgier M; Janssen HL
J Viral Hepat; 2016 Dec; 23(12):1003-1008. PubMed ID: 27502526
[TBL] [Abstract][Full Text] [Related]
29. Three-year efficacy and safety of tenofovir in nucleos(t)ide analog-naïve and nucleos(t)ide analog-experienced chronic hepatitis B patients.
Wang HM; Hung CH; Lee CM; Lu SN; Wang JH; Yen YH; Kee KM; Chang KC; Tseng PL; Hu TH; Chen CH
J Gastroenterol Hepatol; 2016 Jul; 31(7):1307-14. PubMed ID: 26758501
[TBL] [Abstract][Full Text] [Related]
30. Association of Chronic Hepatitis B Infection and Antiviral Treatment With the Development of the Extrahepatic Malignancies: A Nationwide Cohort Study.
Lee DH; Chung SW; Lee JH; Kim HY; Chung GE; Kim MS; Yang BR; Nam JY; Lee YB; Kim YJ; Yoon JH
J Clin Oncol; 2022 Oct; 40(29):3394-3405. PubMed ID: 35561284
[TBL] [Abstract][Full Text] [Related]
31. Treatment of chronic hepatitis B virus infection - Dutch national guidelines.
Buster EH; van Erpecum KJ; Schalm SW; Zaaijer HL; Brouwer JT; Gelderblom HC; de Knegt RJ; Minke Bakker C; Reesink HW; Janssen HL;
Neth J Med; 2008; 66(7):292-306. PubMed ID: 18663260
[TBL] [Abstract][Full Text] [Related]
32. Hepatitis B s antigen kinetics during treatment with nucleos(t)ides analogues in patients with hepatitis B e antigen-negative chronic hepatitis B.
Striki A; Manolakopoulos S; Deutsch M; Kourikou A; Kontos G; Kranidioti H; Hadziyannis E; Papatheodoridis G
Liver Int; 2017 Nov; 37(11):1642-1650. PubMed ID: 28345181
[TBL] [Abstract][Full Text] [Related]
33. Tenofovir has inferior efficacy in adefovir-experienced chronic hepatitis B patients compared to nucleos(t)ide-naïve patients.
Chung GE; Cho EJ; Lee JH; Yoo JJ; Lee M; Cho Y; Lee DH; Kim HY; Yu SJ; Kim YJ; Yoon JH; Zoulim F
Clin Mol Hepatol; 2017 Mar; 23(1):66-73. PubMed ID: 28190329
[TBL] [Abstract][Full Text] [Related]
34. Antiviral effect of entecavir in chronic hepatitis B: influence of prior exposure to nucleos(t)ide analogues.
Reijnders JG; Deterding K; Petersen J; Zoulim F; Santantonio T; Buti M; van Bömmel F; Hansen BE; Wedemeyer H; Janssen HL;
J Hepatol; 2010 Apr; 52(4):493-500. PubMed ID: 20185191
[TBL] [Abstract][Full Text] [Related]
35. Effect of Metabolic Syndrome on the Clinical Outcomes of Chronic Hepatitis B Patients with Nucleos(t)ide Analogues Treatment.
Kim NH; Cho YK; Kim BI; Kim HJ
Dig Dis Sci; 2018 Oct; 63(10):2792-2799. PubMed ID: 29948568
[TBL] [Abstract][Full Text] [Related]
36. Nucleos(t)ide analogue continuous therapy associated with reduced adverse outcomes of chronic hepatitis B.
Su CW; Wu CY; Lin JT; Ho HJ; Wu JC
J Chin Med Assoc; 2020 Feb; 83(2):125-133. PubMed ID: 32015266
[TBL] [Abstract][Full Text] [Related]
37. Reduced risk of relapse after long-term nucleos(t)ide analogue consolidation therapy for chronic hepatitis B.
Chi H; Hansen BE; Yim C; Arends P; Abu-Amara M; van der Eijk AA; Feld JJ; de Knegt RJ; Wong DK; Janssen HL
Aliment Pharmacol Ther; 2015 May; 41(9):867-76. PubMed ID: 25752878
[TBL] [Abstract][Full Text] [Related]
38. Comparison of the efficacy and safety of entecavir and tenofovir in nucleos(t)ide analogue-naive chronic hepatitis B patients with high viraemia: a retrospective cohort study.
Wu IT; Hu TH; Hung CH; Lu SN; Wang JH; Lee CM; Chen CH
Clin Microbiol Infect; 2017 Jul; 23(7):464-469. PubMed ID: 28189857
[TBL] [Abstract][Full Text] [Related]
39. Systematic review: combination therapies for treatment-naïve chronic hepatitis B.
Kumar M; Sarin SK
Aliment Pharmacol Ther; 2008 Jun; 27(12):1187-209. PubMed ID: 18373730
[TBL] [Abstract][Full Text] [Related]
40. Novel machine learning models outperform risk scores in predicting hepatocellular carcinoma in patients with chronic viral hepatitis.
Wong GL; Hui VW; Tan Q; Xu J; Lee HW; Yip TC; Yang B; Tse YK; Yin C; Lyu F; Lai JC; Lui GC; Chan HL; Yuen PC; Wong VW
JHEP Rep; 2022 Mar; 4(3):100441. PubMed ID: 35198928
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
